<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02851394</url>
  </required_header>
  <id_info>
    <org_study_id>Bethenod Ellouze 2014</org_study_id>
    <nct_id>NCT02851394</nct_id>
  </id_info>
  <brief_title>Advantage of Tramadol in Local Analgesia Post-Sternotomy</brief_title>
  <acronym>ATLAS</acronym>
  <official_title>Evaluation Of The Efficacy Of A Bolus Infiltration Of The Anaesthetic Tramadol Associated With Continuous Local Anaesthesia Administered Via A Wound Catheter Following Heart Surgery Via Sternotomy At Dijon Chu Single-Centre, Double-Blind, Randomized, Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <brief_summary>
    <textblock>
      Sternotomy, the reference approach for heart surgery, may induce profound and intense&#xD;
      post-operative pain. One method of analgesia used is patient-controlled intravenous morphine.&#xD;
&#xD;
      The analgesic efficacy of continuous wound infiltration at the sternum following heart&#xD;
      surgery has been demonstrated.&#xD;
&#xD;
      The analgesic catheter placed near the sternotomy wound reduces the consumption of morphine.&#xD;
&#xD;
      The aim of this study is to determine whether a bolus of tramadol associated with the&#xD;
      continuous administration of levobupivacaine via the wound catheter could potentiate the&#xD;
      local anaesthetic effects, thus leading to a decreased consumption of postoperative&#xD;
      intravenous morphine, and a decrease in morphine-related side effects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Consumption of morphine, expressed in milligrams, in the post-operative period</measure>
    <time_frame>48 hour after extubation</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Heart Surgery Via Sternotomy</condition>
  <condition>Post-operative Analgesia</condition>
  <arm_group>
    <arm_group_label>Levobupivacaine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Levobupivacaine + tramadol group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levobupivacaine</intervention_name>
    <arm_group_label>Levobupivacaine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levobupivacaine</intervention_name>
    <arm_group_label>Levobupivacaine + tramadol group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tramadol</intervention_name>
    <arm_group_label>Levobupivacaine + tramadol group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Persons who have provided written consent&#xD;
&#xD;
          -  Patients over 18 years old&#xD;
&#xD;
          -  Patients undergoing heart surgery via sternotomy: aortic valve surgery, mitral valve&#xD;
             surgery, tricuspid valve surgery, atrial myxoma, coronary artery bypass graft, aorta&#xD;
             surgery&#xD;
&#xD;
          -  Patients undergoing emergency or scheduled surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Adults under guardianship&#xD;
&#xD;
          -  Persons without national health insurance cover&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Patients already included in the study once&#xD;
&#xD;
          -  Patients with aortic dissection&#xD;
&#xD;
          -  Patients with mediastinitis or sternal nonunion&#xD;
&#xD;
          -  Patients undergoing heart surgery for the second or more time&#xD;
&#xD;
          -  Patients with local infection or generalized bacteraemia-type infection&#xD;
&#xD;
          -  Patients with hypersensitivity to local anaesthetics or to tramadol or to opiates or&#xD;
             to one of the excipients present in the products used&#xD;
&#xD;
          -  Patients with hypersensitivity to paracetamol or to paracetamol hydrochloride (prodrug&#xD;
             of paracetamol)&#xD;
&#xD;
          -  Patients on antidepressants, gabapentin, pregabalin, neuroleptics&#xD;
&#xD;
          -  Patients with a history of convulsions or epilepsy&#xD;
&#xD;
          -  Patients with preoperative cognitive dysfunction&#xD;
&#xD;
          -  Patients with intracranial hypertension&#xD;
&#xD;
          -  Chronic use of morphines or high-dose steroid or non-steroid anti-inflammatory agents&#xD;
&#xD;
          -  Patients with acute or chronic kidney failure (creatininemia &gt; 170 µmol/L)&#xD;
&#xD;
          -  Patients with liver failure or porphyria&#xD;
&#xD;
          -  Patients under 17 years old&#xD;
&#xD;
          -  Patients with severe respiratory failure&#xD;
&#xD;
          -  Patients treated with a non-selective MAOI (iproniazid), a selective MAOI A&#xD;
             (moclobemid, toloxatone), selective MAO-B inhibitor (Selegiline) or linezolid&#xD;
             (Zyvoxid®)&#xD;
&#xD;
          -  Patients with acute intoxication or an overdose of products that depress the central&#xD;
             nervous system (alcohol, hypnotics, other analgesics…)&#xD;
&#xD;
          -  Patients with severe hypotension&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>July 28, 2016</study_first_submitted>
  <study_first_submitted_qc>July 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2016</study_first_posted>
  <last_update_submitted>October 9, 2017</last_update_submitted>
  <last_update_submitted_qc>October 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tramadol</mesh_term>
    <mesh_term>Levobupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

